LS9 Announces Florida Plant Grand Opening and Receives $4.5 million from Florida Opportunity Fund

LS9 Announces Florida Plant Grand Opening and Receives $4.5 million from Florida Opportunity Fund

May 14, 2012

South san francisco, CA (May 14, 2012) – LS9, Inc., a technology leader in the development of renewable and sustainable products, today announced an investment from the Florida Opportunity Fund's (FOF) Clean Energy Investment Program, and the Grand Opening plans for its facility in Okeechobee, Florida.

Helicos BioSciences Corporation Settles its Patent Litigation Against Pacific Biosciences, Inc.

Helicos BioSciences Corporation Settles its Patent Litigation Against Pacific Biosciences, Inc.

May 14, 2012

Litigation Against Illumina, Life Technologies Continues

Affinnova Announces Record Sales

Affinnova Announces Record Sales

May 17, 2012

WALTHAM, Mass., May 17, 2012 (BUSINESS WIRE) -- Affinnova, Inc., the global leader in innovation software and services, has announced record sales for the prior twelve months ending March, 2012. Total sales increased 43% compared to the previous 12-month period. Non-U.S. sales rose to 18% of the business overall, as Affinnova has aggressively expanded its operations in Europe, hiring staff in the United Kingdom, France and Germany.

BG Medicine, Inc. Announces Availability of Galectin-3 Diagnostic Testing Through Mayo Medical Laboratories

BG Medicine, Inc. Announces Availability of Galectin-3 Diagnostic Testing Through Mayo Medical Laboratories

May 14, 2012

WALTHAM, Mass., May 14, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today that Mayo Medical Laboratory (Mayo) now offers galectin-3 testing services to its laboratory customers and physicians. Mayo will offer the BGM Galectin-3TM test, which was cleared by the U.S.

BG Medicine Announces Publication of First Study on Use of Galectin-3 inSelection of Drug Therapy in Heart Failure

BG Medicine Announces Publication of First Study on Use of Galectin-3 inSelection of Drug Therapy in Heart Failure

May 14, 2012

WALTHAM, Mass., May 14, 2012 (GlobeNewswire via COMTEX) -- BG Medicine, Inc.

Eleven Biotherapeutics Secures $20 Million and Expands Series A Financing

Eleven Biotherapeutics Secures $20 Million and Expands Series A Financing

May 8, 2012

Company to Advance its lead Drug Candidate, EBI-005, into Clinic Development for Dry Eye Disease

US Scientists Who Mean Business

US Scientists Who Mean Business

May 6, 2012

 

Vaccine Could Stop Nicotine from Reaching the Brain

Vaccine Could Stop Nicotine from Reaching the Brain

May 1, 2012

The new antismoking technique uses nanoparticles to trigger an immune response.

By Conor Myhrvold

Seahorse Announces the XF Glycolysis Stress Test Kit

Seahorse Announces the XF Glycolysis Stress Test Kit

April 25, 2012

BILLERICA, Mass., April 25, 2012 -- /PRNewswire/ -- Seahorse Bioscience, the leader in cellular bioenergetic measurements, announced the launch of its newest stress test kit at the American Association of Cancer Research (AACR) Annual Meeting 2012. The XF Glycolysis Stress Test Kit is the first Standard for measuring glycolytic capacity in cells.

Dr. Noubar Afeyan, Flagship's Managing Partner and CEO, speaking on Investor Panel at BIO World Congress on Industrial Biotechnology & Bioprocessing

Dr. Noubar Afeyan, Flagship's Managing Partner and CEO, speaking on Investor Panel at BIO World Congress on Industrial Biotechnology & Bioprocessing

April 30, 2012

 Click here to see announcement.